CN115068420A - Tylosin tartrate solution for livestock and poultry and preparation method thereof - Google Patents
Tylosin tartrate solution for livestock and poultry and preparation method thereof Download PDFInfo
- Publication number
- CN115068420A CN115068420A CN202210894668.XA CN202210894668A CN115068420A CN 115068420 A CN115068420 A CN 115068420A CN 202210894668 A CN202210894668 A CN 202210894668A CN 115068420 A CN115068420 A CN 115068420A
- Authority
- CN
- China
- Prior art keywords
- tylosin tartrate
- concentration
- livestock
- sodium
- tartrate solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ICVKYYINQHWDLM-KBEWXLTPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 ICVKYYINQHWDLM-KBEWXLTPSA-N 0.000 title claims abstract description 63
- 229960001717 tylosin tartrate Drugs 0.000 title claims abstract description 63
- 244000144972 livestock Species 0.000 title claims abstract description 26
- 244000144977 poultry Species 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 42
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 32
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960000502 poloxamer Drugs 0.000 claims abstract description 21
- 229920001983 poloxamer Polymers 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 21
- 239000001509 sodium citrate Substances 0.000 claims abstract description 21
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 21
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 21
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 18
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 18
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 18
- 229960004063 propylene glycol Drugs 0.000 claims abstract description 16
- 239000008213 purified water Substances 0.000 claims abstract description 15
- -1 T-80 Chemical compound 0.000 claims abstract description 6
- 235000011083 sodium citrates Nutrition 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims description 18
- 239000002244 precipitate Substances 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 3
- 238000009395 breeding Methods 0.000 abstract description 5
- 230000001488 breeding effect Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical class O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 3
- GUARTUJKFNAVIK-QPTWMBCESA-N Tulathromycin A Chemical compound C1[C@](OC)(C)[C@@](CNCCC)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)NC[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C GUARTUJKFNAVIK-QPTWMBCESA-N 0.000 description 2
- 229930194936 Tylosin Natural products 0.000 description 2
- 239000004182 Tylosin Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960002859 tulathromycin Drugs 0.000 description 2
- 229960004059 tylosin Drugs 0.000 description 2
- 235000019375 tylosin Nutrition 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000408944 Clostridium putrefaciens Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202942 Mycoplasma synoviae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000221696 Sclerotinia sclerotiorum Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a tylosin tartrate solution for livestock and poultry and a preparation method thereof, wherein the tylosin tartrate solution for livestock and poultry comprises poloxamer, 1, 2-propylene glycol, T-80, sodium benzoate, sodium citrate, sodium sulfite, L-tartaric acid, purified water and tylosin tartrate powder; the concentration of tylosin tartrate raw powder in the tylosin tartrate solution is 50 g/L-200 g/L, the concentration of poloxamer is 5 g/L-35 g/L, the concentration of sodium benzoate is 0.5 g/L-3 g/L, the concentration of 1, 2-propylene glycol is 50 g/L-250 g/L, the concentration of T-80 is 5 g/L-30 g/L, the concentration of sodium citrate is 1 g/L-5 g/L, the concentration of sodium sulfite is 1 g/L-6 g/L, the concentration of L-tartaric acid is 10 g/L-55 g/L, and the concentration of purified water is 750 g/L-900 g/L, the invention provides a production process of the tylosin tartrate solution for large-scale breeding group administration, so as to overcome the poor water solubility of the existing preparation, the water line is easy to block, and the use mode is limited in practical application.
Description
Technical Field
The invention relates to the technical field of veterinary drugs, in particular to a tylosin tartrate solution for livestock and poultry, and also relates to a preparation method of the tylosin tartrate solution for livestock and poultry.
Background
Tylosin tartrate is a biotransformation derivative of tylosin A, and belongs to a novel special antibiotic for macrolides animals. The antibacterial mechanism is the same as other macrolide antibiotics, and the antibacterial agent can be combined with the sensitive sclerotinia sclerotiorum 50S subunit to interfere the ribosome transpeptidation function, thereby inhibiting peptide chain synthesis and extension and further influencing bacterial protein synthesis; the antibacterial spectrum of the bacillus subtilis is similar to that of tylosin, and has stronger antibacterial effects on staphylococcus aureus (including penicillin-resistant strains), pneumococcus, streptococcus, bacillus anthracis, erysipelothrix rhusiopathiae, listeria, clostridium putrefaciens, clostridium aeroma and the like. The product is effective on other antibiotic-resistant gram-positive bacteria, and has strong antibacterial activity on mycoplasma septicum and mycoplasma synoviae. Clinical application in farms proves that the tavermectin tartrate has the advantages of low toxicity, high efficiency, low residue and the like, has no cross resistance with other macrolide antibiotics, and is a better medicine for treating respiratory tract and digestive tract infection.
The tylosin tartrate formulations sold on the market are mainly powder and premix. The tylosin tartrate can be dissolved in water, but due to the problems of immature production process and the like, the tylosin tartrate in industrial production is doped with insoluble impurities, so that the water solubility is very poor, and the bioavailability of the product is low. However, at present, the animal breeding industry mostly uses a doser for drinking water and feeding, the solubility of the tylosin tartrate powder and the premix is very low, the breeding requirement of large-scale breeding on group feeding cannot be met, and even drinking water pipelines are blocked. The water solubility is poor, so that the bioavailability of the tavermectin is low, the application mode in practical application is limited, the application effect is poor, and the application and development of the tavermectin in the breeding development are influenced. Therefore, the development of a tylosin tartrate solution which meets the requirements of the breeding industry and has high stability is very necessary.
Disclosure of Invention
The invention aims to provide a tylosin tartrate solution for livestock and poultry, develop a new tylosin tartrate preparation, enrich the variety of the tylosin tartrate preparation, meet the drug use requirements of the livestock and poultry and the group drug administration requirements of large-scale culture, and solve the problems in the background art.
In order to achieve the purpose, the invention provides the following technical scheme:
a tylosin tartrate solution for livestock and poultry comprises poloxamer, 1, 2-propylene glycol, T-80, sodium benzoate, sodium citrate, sodium sulfite, L-tartaric acid, purified water and tylosin tartrate powder.
Further, the concentration of the tylosin tartrate powder in the tylosin tartrate solution is 50-200 g/L.
Further, the concentration of the poloxamer is 5 g/L-35 g/L, the concentration of sodium benzoate is 0.5 g/L-3 g/L, the concentration of 1, 2-propylene glycol is 50 g/L-250 g/L, the concentration of T-80 is 5 g/L-30 g/L, the concentration of sodium citrate is 1 g/L-5 g/L, the concentration of sodium sulfite is 1 g/L-6 g/L, the concentration of L-tartaric acid is 10 g/L-55 g/L, and the concentration of purified water is 750 g/L-900 g/L.
Further, the addition standards of sodium citrate, sodium sulfite and L-tartaric acid are as follows: calculated by tylosin tartrate pure product, the product is completely clear and transparent under 10000ppm of solubility, and no visible precipitate exists at the bottom of a beaker after standing for 6 hours; at a solubility of 20000ppm, the beaker was cloudy and opaque, and no visible precipitate was visible to the naked eye on standing for 6 hours.
Further, the proportion of the raw tylosin tartrate powder to the poloxamer is 5:1, and the proportion of the poloxamer to the sodium benzoate is 10: 1.
Further, the ratio of the sodium citrate to the sodium sulfite to the L-tartaric acid is 1.5: 2: 15.
a preparation method of tylosin tartrate solution for livestock and poultry comprises the following steps:
s1, adding poloxamer into the purified water, and stirring to dissolve;
s2, sequentially adding 1, 2-propylene glycol, T-80, sodium benzoate, sodium citrate, sodium sulfite and L-tartaric acid, stirring to completely dissolve, and continuously stirring for about 10 minutes after dissolving;
s3, dissolving tylosin tartrate powder in the step S2, stirring while adding, stirring for 20-30 minutes to completely dissolve, filtering and subpackaging.
Further, stirring in the step S2 is performed by using a magnetic stirrer for 10 minutes, and the mixture is clear and transparent; standing for 6 hours until no visible precipitate is formed at the bottom of the beaker.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a production process of tylosin tartrate solution for large-scale aquaculture group administration, which aims to solve the problems of poor water solubility, easy water line blockage and limited use mode in practical application of the existing preparation.
The invention develops a new preparation of the tylosin tartrate, enriches the variety of the preparation of the tylosin tartrate, and meets the medication requirements of livestock and poultry and the group administration requirements of large-scale culture.
Drawings
FIG. 1 is a flow chart of the preparation of a tylosin tartrate solution for livestock and poultry according to the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Referring to fig. 1, the present invention provides a technical solution:
a tylosin tartrate solution for livestock and poultry comprises 15g of poloxamer, 120g of 1, 2-propylene glycol, T-8010 g of sodium benzoate, 1.5g of sodium citrate, 2g of sodium sulfite, 15g of L-tartaric acid, 850g of purified water and 70g of tylosin tartrate powder per liter of solution.
Further, the concentration of the raw tylosin tartrate powder in the tylosin tartrate solution is 50-200 g/L.
Further, the concentration of the poloxamer is 5 g/L-35 g/L, the concentration of sodium benzoate is 0.5 g/L-3 g/L, the concentration of 1, 2-propylene glycol is 50 g/L-250 g/L, the concentration of T-80 is 5 g/L-30 g/L, the concentration of sodium citrate is 1 g/L-5 g/L, the concentration of sodium sulfite is 1 g/L-6 g/L, the concentration of L-tartaric acid is 10 g/L-55 g/L, and the concentration of purified water is 750 g/L-900 g/L.
Further, the addition standards of sodium citrate, sodium sulfite and L-tartaric acid are as follows: calculated by tylosin tartrate pure product, the product is completely clear and transparent under 10000ppm of solubility, and no visible precipitate exists at the bottom of a beaker after standing for 6 hours; at a solubility of 20000ppm, the beaker was cloudy and opaque, and no visible precipitate was visible to the naked eye on standing for 6 hours.
Further, the proportion of the tylosin tartrate raw powder to the poloxamer is 4.66:1, and the proportion of the poloxamer to the sodium benzoate is 10: 1.
Further, the ratio of the 1, 2-propylene glycol to the raw tylosin tartrate powder is 12: 7.
Further, the ratio of the sodium citrate to the sodium sulfite to the L-tartaric acid is 1.5: 2: 15.
the invention also provides a preparation method of the tylosin tartrate solution for livestock and poultry, which comprises the following steps:
s1, adding poloxamer into the purified water, and stirring to dissolve;
s2, sequentially adding 1, 2-propylene glycol, T-80, sodium benzoate, sodium citrate, sodium sulfite and L-tartaric acid, stirring to completely dissolve, and continuously stirring for about 10 minutes after dissolving;
s3, dissolving tylosin tartrate powder in the step S2, stirring while adding, stirring for 20-30 minutes to completely dissolve, filtering and subpackaging.
Further, stirring in the step S2 is performed by using a magnetic stirrer for 10 minutes, and the mixture is clear and transparent; standing for 6 hours until no visible precipitate is formed at the bottom of the beaker.
Example 2
The difference from example 1 is:
a tylosin tartrate solution for livestock and poultry comprises 10g of poloxamer, 85g of 1, 2-propylene glycol, 85g of T-8010 g of sodium benzoate, 1g of sodium citrate, 1.3g of sodium sulfite, 10g of L-tartaric acid, 800g of purified water and 50g of tylosin tartrate powder per liter of solution.
Example 3
The difference from example 1 is:
a tylosin tartrate solution for livestock and poultry comprises 20g of poloxamer, 100g of 1, 2-propylene glycol, T-8020 g, 2g of sodium benzoate, 1.5g of sodium citrate, 2g of sodium sulfite, 15g of L-tartaric acid, 850g of purified water and 100g of tylosin tartrate powder per liter of the solution.
Example 4
The difference from example 1 is:
a tylosin tartrate solution for livestock and poultry comprises 30g of poloxamer, 200g of 1, 2-propylene glycol, 1-8010 g of T-8010 g of sodium benzoate, 1g of sodium citrate, 1.3g of sodium sulfite, 10g of L-tartaric acid, 900g of purified water and 150g of tylosin tartrate powder per liter of solution.
Example 5
The difference from example 1 is:
a tylosin tartrate solution for livestock and poultry comprises 35g of poloxamer, 250g of 1, 2-propylene glycol, 250g of T-8030 g of sodium benzoate, 3.5g of sodium citrate, 6g of sodium sulfite, 50g of L-tartaric acid, 750g of purified water and 175g of tylosin tartrate powder per liter of solution.
The purification method of the tylosin tartrate comprises the following steps:
dissolving a crude product of the tavermectin by using ethyl acetate and/or butyl acetate, adding column layer chromatography silica gel, fully mixing, evaporating to dryness, and then loading to a column by a dry method;
gradient elution is carried out on the silica gel column after the silica gel column is loaded by the eluent, and the obtained elution fractions are collected in sections and monitored;
and thirdly, carrying out rotary evaporation on the elution fraction containing the high-purity tulathromycin to obtain the high-purity tulathromycin.
The crude tylosin crude product solution is mixed with column layer chromatography silica gel according to the mass ratio of 1:1-1:4, and the specification of the column layer chromatography silica gel is that the particle size is 100-300 meshes.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. The tylosin tartrate solution for livestock and poultry is characterized by comprising poloxamer, 1, 2-propylene glycol, T-80, sodium benzoate, sodium citrate, sodium sulfite, L-tartaric acid, purified water and tylosin tartrate powder.
2. The tylosin tartrate solution for livestock and poultry according to claim 1, wherein the concentration of tylosin tartrate raw powder in the tylosin tartrate solution is 50 to 200 g/L.
3. The tylosin tartrate solution for livestock and poultry according to claim 1, wherein the concentration of poloxamer is 5 g/L-35 g/L, the concentration of sodium benzoate is 0.5 g/L-3 g/L, the concentration of 1, 2-propylene glycol is 50 g/L-250 g/L, the concentration of T-80 is 5 g/L-30 g/L, the concentration of sodium citrate is 1 g/L-5 g/L, the concentration of sodium sulfite is 1 g/L-6 g/L, the concentration of L-tartaric acid is 10 g/L-55 g/L, and the concentration of purified water is 750 g/L-900 g/L.
4. The tylosin tartrate solution for livestock and poultry according to claim 1, wherein the addition criteria of sodium citrate, sodium sulfite and L-tartaric acid are: calculated by tylosin tartrate pure product, the product is completely clear and transparent under 10000ppm of solubility, and no visible precipitate exists at the bottom of a beaker after standing for 6 hours; at a solubility of 20000ppm, the beaker was cloudy and opaque, and no visible precipitate was visible to the naked eye on standing for 6 hours.
5. The tylosin tartrate solution for livestock and poultry according to claim 1, wherein the ratio of the raw tylosin tartrate powder to the poloxamer is 5:1, and the ratio of the poloxamer to sodium benzoate is 10: 1.
6. Tylosin tartrate solution for livestock and poultry according to claim 1 wherein the ratio of sodium citrate, sodium sulfite and L-tartaric acid is 1.5: 2: 15.
7. the preparation method of the tylosin tartrate solution for livestock and poultry according to any one of claims 1 to 6, which is characterized by comprising the following steps:
s1, adding poloxamer into the purified water, and stirring to dissolve;
s2, sequentially adding 1, 2-propylene glycol, T-80, sodium benzoate, sodium citrate, sodium sulfite and L-tartaric acid, stirring to completely dissolve, and continuously stirring for about 10 minutes after dissolving;
s3, dissolving tylosin tartrate powder in the step S2, stirring while adding, stirring for 20-30 minutes to completely dissolve, filtering and subpackaging.
8. The tylosin tartrate solution for livestock and poultry according to claim 7, wherein: stirring in the step S2 for 10 minutes by adopting a magnetic stirrer, and clarifying and transparent; standing for 6 hours until no visible precipitate is formed at the bottom of the beaker.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210894668.XA CN115068420A (en) | 2022-07-27 | 2022-07-27 | Tylosin tartrate solution for livestock and poultry and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210894668.XA CN115068420A (en) | 2022-07-27 | 2022-07-27 | Tylosin tartrate solution for livestock and poultry and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115068420A true CN115068420A (en) | 2022-09-20 |
Family
ID=83242982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210894668.XA Pending CN115068420A (en) | 2022-07-27 | 2022-07-27 | Tylosin tartrate solution for livestock and poultry and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068420A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432150A (en) * | 2012-08-06 | 2013-12-11 | 四川联美生物药业有限公司 | Compound medicine of synergistic tartaric acid tylosin soluble powder |
| CN108524443A (en) * | 2017-03-31 | 2018-09-14 | 佛山市南海东方澳龙制药有限公司 | A kind of tylosin injection and preparation method thereof, application |
| CN114642641A (en) * | 2022-05-24 | 2022-06-21 | 山东国邦药业有限公司 | Tylosin tartrate water-soluble granules and preparation method thereof |
-
2022
- 2022-07-27 CN CN202210894668.XA patent/CN115068420A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432150A (en) * | 2012-08-06 | 2013-12-11 | 四川联美生物药业有限公司 | Compound medicine of synergistic tartaric acid tylosin soluble powder |
| CN108524443A (en) * | 2017-03-31 | 2018-09-14 | 佛山市南海东方澳龙制药有限公司 | A kind of tylosin injection and preparation method thereof, application |
| CN114642641A (en) * | 2022-05-24 | 2022-06-21 | 山东国邦药业有限公司 | Tylosin tartrate water-soluble granules and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI453015B (en) | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | |
| CN102008445B (en) | Amoxicillin soluble powder as well as preparation method and application thereof | |
| CN105168143A (en) | Amoxicillin preparation and preparation method thereof | |
| CN109170228A (en) | A kind of liquid compound acidulant and its preparation process with strong buffer capacity | |
| CN107412189B (en) | Taste-masking enrofloxacin soluble powder and preparation method thereof | |
| CN103417512B (en) | A kind of Biomox and preparation method thereof | |
| CN101843589A (en) | Ceftizoxime sodium composition sterile powder for injection | |
| CN101611766B (en) | Production method of enteric-coated kitasamycin for feed | |
| CN1947699A (en) | Method for producing water soluble fluorophenylnico | |
| CN112220755A (en) | Doxycycline hydrochloride soluble powder and preparation method thereof | |
| CN115068420A (en) | Tylosin tartrate solution for livestock and poultry and preparation method thereof | |
| CN101955493A (en) | Method for preparing cefotiam hexetil hydrochloride and composition of cefotiam hexetil hydrochloride | |
| CN104586777A (en) | Ceftiofur hydrochloride powder injection as well as preparation method and application thereof | |
| CN102268020B (en) | Ceftiofur acetoxy ethyl ester and preparation method thereof | |
| CN102716075B (en) | Ceftizoxime sodium-containing pharmaceutical composition | |
| KR100371090B1 (en) | The composition of antibacterial complex for animal | |
| CN103127114B (en) | Medicinal composition including piperacillin sodium and sulbactam sodium | |
| CN104606149A (en) | Tulathromycin bacteria-free powder and preparation method thereof | |
| CN101700223A (en) | Erythromycin cydocarbonate injection and preparation process thereof | |
| CN103040818B (en) | Drug composition containing amoxicillin sodium and clavulanate potassium compound | |
| CN113318106B (en) | Long-acting compound amoxicillin oil suspension injection for animals and preparation method thereof | |
| CN115707389B (en) | Phage gel and preparation method and application thereof | |
| CN107652306B (en) | Cefuroxime sodium crystal compound | |
| CN106214628B (en) | Doxycycline hydrochloride injection for livestock and preparation method thereof | |
| KR20010078497A (en) | The composition of antibacterial complex for animal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |
|
| RJ01 | Rejection of invention patent application after publication |